A scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Cooperative Group.

Diest, Paul J. van; Dam, Peter van; Henzen‐Logmans, S. C.; Berns, Els M.J.J.; Burg, M.E.L. van der; Green, J.; Vergote, Ignace

doi:10.1136/jcp.50.10.801

Cited by 176 publications

(115 citation statements)

References 9 publications

Supporting

Mentioning

111

Contrasting

Unclassified

Order By: Relevance

“…When a semiquantitative measure (> 5%) was applied, the prognostic effect was not significant (P = 0.64), which is similar to other reports (Hunt et al, 1996). van Diest et al (1997) highlight the problems with scoring immunohistochemistry and suggest a protocol to reduce the variability between published papers. In this study, we have used only the defined staining pattern for each antibody, reviewed the complete tumour on the section stained and used a cut-off determined by clinical parameters.…”

Section: Discussionsupporting

confidence: 72%

Prognostic significance of the bcl-2 apoptotic family of proteins in primary and recurrent cervical cancer

Crawford

Caldwell²,

Iles³

et al. 1998

Br J Cancer

View full text Add to dashboard Cite

bcl-2 is one of a family of genes that control the apoptotic threshold of a cell. bcl-2 protein and its anti-apoptotic homologue, mcl-1, with the pro-apoptotic protein, bax, are thought to function by forming homo-and heterotypic dimers that then control the progression to apoptosis. p53 is also involved as a down-regulator of bcl-2 and a promoter of bax. To determine the effect of these apoptotic mechanisms, we used immunohistochemistry to determine the prognostic significance of the expression of bcl-2, mcl-1, bax and p53 in primary and recurrent cervical cancer. Tissues from 46 patients with primary cervical cancer and 28 women with recurrent carcinoma were stained for bcl-2, mcl-1, bax and p53. Kaplan-Meier survival analysis was performed using the log-rank test for differences between groups. In the primary disease group, positive staining for bcl-2 was associated with a better 5-year survival (bcl-2 +ve, 84% vs bcl-2 -ve, 53%, P = 0.03). Positive staining for p53 was associated with a survival disadvantage (p53 +ve, 4-year survival 38% vs p53 -ve, 4-year survival 78%, P= 0.02). mcl-1 and bax staining were not useful as prognostic indicators in primary disease. No marker was prognostic in recurrent disease. Positive bcl-2 staining defines a group of patients with primary disease with a good prognosis. p53, an activator of the bax promoter, identifies a group with a worse outcome. In recurrent disease, none of the markers reflected prognosis.

show abstract

Section: Discussionsupporting

confidence: 72%

Prognostic significance of the bcl-2 apoptotic family of proteins in primary and recurrent cervical cancer

Crawford

Caldwell²,

Iles³

et al. 1998

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…Within these 'hot spots' ten random chosen fields were analysed based on the guidelines from the Gynaecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer (van Diest et al, 1997). The following parameters were measured: vessel counts, vessel perimeter and endothelial stained area.…”

Section: Digital Image Analysis and Immunohistochemical Evaluationmentioning

confidence: 99%

Quantification and prognostic relevance of angiogenic parameters in invasive cervical cancer

Tjalma

Marck²,

Weyler³

et al. 1998

Br J Cancer

Self Cite

View full text Add to dashboard Cite

Summary Tumour stromal neovascularization was investigated in 114 invasive and 20 in situ carcinomas of the uterine cervix by staining representative sections with the specific endothelial marker anti CD31 (clone JC/70A, isotope IgG1). A digital image analyser was used to measure the immunoreactivity. The following parameters were determined in the 'hot spots': vessel counts, vessel perimeter and endothelial stained area (expressed per mm2). The results were correlated with clinical and histopathological data. There was no significant relationship between the histopathological findings (tumour histology, tumour differentiation, FIGO stage, presence of lymph node metastasis or lymphovascular space involvement) and the median vessel count. In a univariate analysis all angiogenesis parameters had prognostic value: a higher vascularity was associated with worse prognosis (P < 0.05). Multiple regression analysis showed that vascular permeation (P < 0.001) and the median vessel count (P = 0.005) were the most important prognostic indicators. In the future these criteria may be used for selection of patients for anti-angiogenesis therapy.

show abstract

“…The 5% cut-off was chosen because it conforms to the International European Organization for Research and Treatment of CancerGynaecological Cancer Cooperative Group recommendations (van Diest et al, 1997). Furthermore, this cut-off was used as the criterion to distinguish positive and negative immunohistochemical staining in our previous studies of prostate cancer (Cornford et al, 2000), thus ensuring consistency of criteria between studies.…”

Section: Patient Cohortmentioning

confidence: 99%

Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement

et al. 2009

View full text Add to dashboard Cite

Background: This study was performed to test the hypothesis that expression of small heat shock protein Hsp-27 is, at diagnosis, a reliable predictive biomarker of clinically aggressive prostate cancer. Methods: A panel of tissue microarrays constructed from a well-characterised cohort of 553 men with conservatively managed prostate cancer was stained immunohistochemically to detect Hsp-27 protein. Hsp-27 expression was compared with a series of pathological and clinical parameters, including outcome. Results: Hsp-27 staining was indicative of higher Gleason score ( P <0.001). In tissue cores having a Gleason score >7, the presence of Hsp-27 retained its power to independently predict poor clinical outcome ( P <0.002). Higher levels of Hsp-27 staining were almost entirely restricted to cancers lacking ERG rearrangements ( χ 2 trend=31.4, P <0.001), although this distribution did not have prognostic significance. Interpretation: This study has confirmed that, in prostate cancers managed conservatively over a period of more than 15 years, expression of Hsp-27 is an accurate and independent predictive biomarker of aggressive disease with poor clinical outcome ( P <0.001). These findings suggest that apoptotic and cell-migration pathways modulated by Hsp-27 may contain targets susceptible to the development of biologically appropriate chemotherapeutic agents that are likely to prove effective in treating aggressive prostate cancers.

show abstract

A scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Cooperative Group.

Cited by 176 publications

References 9 publications

Prognostic significance of the bcl-2 apoptotic family of proteins in primary and recurrent cervical cancer

Prognostic significance of the bcl-2 apoptotic family of proteins in primary and recurrent cervical cancer

Quantification and prognostic relevance of angiogenic parameters in invasive cervical cancer

Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement

Contact Info

Product

Resources

About